Healthcare and Pharmaceuticals
A Strong Financial Perspective for Healthcare and Pharmaceuticals.
Sector-specific support for tax, reimbursement, investment, and financial processes.
A Financial and Tax Approach for Healthcare and Pharmaceutical Businesses
Healthcare and pharmaceutical businesses operate under detailed regulatory requirements, public reimbursement systems, changing pricing rules, significant investment and R&D needs, and sector-specific tax treatment. These conditions call for sound financial management and regular monitoring of applicable legislation.
At Next CPA, we support healthcare providers, pharmaceutical companies, and related businesses with tax obligations, financial processes, and assessment of the financial effects of regulatory changes.
For healthcare providers, SGK and the Health Implementation Communiqué (SUT), service revenue and collection, staffing costs, investment, and cost-center reporting can be significant. For pharmaceutical companies, product pricing and reimbursement, inventory and expiry-related financial risks, imports and foreign exchange, R&D, product profitability, and related-party transactions can affect financial planning.
We assess tax, certification, VAT, the financial effects of reimbursement processes, R&D and investment incentives, inventory and costing, reporting, and cash flow in light of each business model and current legislation.
Organizations We Support
- Private hospital operators
- Medical centers, private clinics, and polyclinics
- Diagnostic and imaging centers and medical laboratories
- Pharmaceutical companies and manufacturers
- Pharmaceutical importers and wholesalers
- Medical device and medical product manufacturers, importers, and distributors
Financial Effects of SGK Reimbursement and Healthcare Rules
- The SGK reimbursement system and changes to the Health Implementation Communiqué (SUT) can affect healthcare providers' revenue, collections, and cash flow.
- We assess the accounting, tax, and reporting effects of reimbursement terms, service revenue, and SGK receivables under applicable rules.
- Our work concerns financial effects; it does not include medical coding, healthcare authorization, medical eligibility, or healthcare licensing.
Tax, VAT, and Certification
- Tax treatment for healthcare services and pharmaceutical activities may differ according to the service, transaction, and business model.
- We assess corporate tax, VAT, exemptions and refunds or offsets, withholding, Full-Scope Tax Certification (Tam Tasdik), and other YMM certification needs under current legislation and the accounting records.
- We provide tax advisory and certification work within the agreed and applicable scope.
Financial Effects of Pharmaceutical Pricing and Reimbursement
- Pricing rules, SGK reimbursement decisions, and a product's reimbursement status can affect pharmaceutical companies' revenue and cash flow.
- Using current rules and business information, we assess product-level revenue, budgets and forecasts, cash flow, and financial reporting effects.
- We do not present changing prices or reimbursement rules as fixed facts or manage licensing and reimbursement applications; our focus is their financial and tax effects.
Inventory, Costing, and Financial Reporting
- Inventory valuation, expiry dates, import costs, and foreign exchange movements can affect the financial results of pharmaceutical and medical-product businesses.
- We assess the accounting, provision, and tax effects of inventory records, slow-moving products, and products approaching expiry.
- For healthcare providers, we support service or cost-center revenue and expense analysis, budget-to-actual comparisons, and management reporting. We do not provide medical safety or technical quality-control services.
R&D, Investment, and Incentives
- The tax treatment of R&D and investment expenditure in pharmaceuticals, biotechnology, medical technology, and healthcare depends on the activity and investment.
- We assess potentially applicable R&D and investment incentives, tax exemptions and deductions, VAT, fixed-asset records, and depreciation under current requirements.
- We do not imply that an incentive applies to every business or guarantee eligibility or results.
Financial Planning and Strategic Transactions
- Investments in hospitals, clinics, manufacturing facilities, or products, as well as mergers, acquisitions, and restructurings, can have financial and tax consequences.
- Based on the relevant business information, we support assessment of investment budgets, cash-flow projections, financial models, and tax effects.
- For pharmaceutical companies, we address transfer pricing and related-party transactions only where the client and agreed service scope are confirmed; we do not broker or execute transactions.
Clearer financial insight for healthcare and pharmaceutical businesses
We assess tax, certification, inventory and costing, financial reporting, and advisory needs in light of each healthcare provider's or pharmaceutical company's activities.
Let's assess your financial decisions in healthcare and pharmaceuticals.
Let's discuss your tax, reimbursement, certification, investment, and reporting needs in light of your business model.